Rigosertib Sodium: Clinical Trials

17 trials of Rigosertib Sodium, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed. 11 Phase 1, 4 Phase 2, 2 Phase 3, 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Phase 111Completed 11
Phase 24Completed 4
Phase 32Completed 2
Early Phase 11Completed 1

Follow Rigosertib Sodium: new trials by email Literature Review of Rigosertib Sodium trials Research Report on Rigosertib Sodium

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Rigosertib in Patients With Recessive Dystrophic Epidermolysis Bullosa Associated SCC
Rigosertib Sodium, Quality-of-Life Assessment - Recessive Dystrophic Epidermolysis Bullosa
Early Phase 1CompletedThomas Jefferson University32021-08-242025-08-01
Metabolism and Excretion of [14C]-Rigosertib After Infusion to Volunteers
rigosertib - Healthy
Phase 1CompletedTraws Pharma, Inc.62014-01-012017-06-23
Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer
oral rigosertib, cisplatin, Radiotherapy - Head and Neck Neoplasms, Carcinoma, Squamous Cell
Phase 1CompletedTraws Pharma, Inc.22014-01-012017-06-23
Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine
rigosertib sodium - Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts
Phase 3CompletedTraws Pharma, Inc.672013-08-012020-06-30
Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs
Oral rigosertib - Myelodysplastic Syndromes
Phase 2CompletedTraws Pharma, Inc.452013-07-012021-06-16
Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome
rigosertib - Myelodysplastic Syndrome, MDS
Phase 2CompletedTraws Pharma, Inc.822012-05-012017-06-26
Gemcitabine and ON 01910.Na in Previously Untreated Metastatic Pancreatic Cancer
ON 01910.Na, Gemcitabine - Metastatic Pancreatic Adenocarcinoma
Phase 3CompletedTraws Pharma, Inc.1602011-05-012016-08-04
Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors
rigosertib - Solid Tumor
Phase 1CompletedTraws Pharma, Inc.682010-07-012017-06-23
Safety and Efficacy of 72-hour and 120-hour Infusion of Rigosertib in Acute Myeloid Leukemia (AML) and Acute Lymphoid Leukemia (ALL)
rigosertib - Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Phase 1 / Phase 2CompletedTraws Pharma, Inc.302010-07-012017-06-26
Safety of 24-hour Infusion of ON 01910.Na in Combination With Gemcitabine in Advanced Solid Tumors
ON 01910.Na, Gemcitabine - Solid Tumor
Phase 1CompletedTraws Pharma, Inc.102010-01-012017-06-23
Effect of 2-h Infusion of ON 01910.Na in Ovarian Cancer Patients
ON 01910.Na - Ovarian Cancer
Phase 2CompletedTraws Pharma, Inc.12009-03-012017-07-21
Dose Escalation Study of Gemcitabine and ON 01910.Na in Solid Tumors
gemcitabine, ON 01910.Na - Malignant Neoplasmas, Solid Tumors
Phase 1CompletedTraws Pharma, Inc.392009-01-012017-06-23
Phase I Study of ON 01910.Na in Refractory Leukemia or Myelodysplastic Syndrome (MDS)
ON 01910.Na - Acute Myelocytic Leukemia, Acute Lymphocytic Leukemia
Phase 1CompletedTraws Pharma, Inc.222008-10-012018-01-10
Safety of ON 01910.Na and Irinotecan or ON 01910.Na and Oxaliplatin in Patients With Hepatoma
irinotecan and ON 01910.Na, oxaliplatin and ON 01910.Na - Hepatoma, Advanced Solid Tumor
Phase 1CompletedTraws Pharma, Inc.162008-06-012017-06-23
Safety Study of ON 01910.Na in Combination With Irinotecan or Oxaliplatin
ON 01910.Na and irinotecan, ON 01910.Na and oxaliplatin - Advanced Solid Tumors
Phase 1CompletedTraws Pharma, Inc.182008-02-012017-06-23
Safety of ON 01910.Na as a 3-day Infusion in Patients With Advanced Cancer
rigosertib sodium - Advanced Cancer, Solid Tumors
Phase 1CompletedTraws Pharma, Inc.292006-08-012017-06-23
Safety of 24-Hour Infusion of ON 01910.Na in Patients With Advanced Cancer
rigosertib sodium - Solid Tumors, Advanced Cancer
Phase 1CompletedTraws Pharma, Inc.422006-06-012017-06-23

Conditions studied

Myelodysplastic Syndromes (4)  ·  Neoplasms (4)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Squamous Cell (1)  ·  Chromosome 8, trisomy (1)  ·  Cytopenia (1)  ·  Epidermolysis Bullosa Dystrophica (1)  ·  Head and Neck Neoplasms (1)  ·  Leukemia (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Leukemia, Myelomonocytic, Chronic (1)

Sponsors

Traws Pharma, Inc. (16)  ·  Thomas Jefferson University (1)

Countries

United States (17)  ·  France (2)  ·  Germany (2)  ·  Australia (1)  ·  Denmark (1)  ·  Hungary (1)  ·  India (1)  ·  Italy (1)  ·  Russia (1)  ·  Spain (1)  ·  Sweden (1)  ·  Ukraine (1)

Top investigators

Antonio Jimeno, MD, PhD (4)  ·  Sridhar Mani, MD (3)  ·  Steven M. Fruchtman, MD (3)  ·  Francois Wilhelm, MD, PhD (1)  ·  Gregory P. Sutton, MD (1)  ·  Jorge Cortes, MD (1)  ·  Lawrence P. Leichman, MD (1)  ·  Lewis R. Silverman, MD (1)  ·  Neda Nikbakht, MD, PhD (1)  ·  Pamela N. Munster, MD (1)  ·  Takao Ohnuma, M.D. (1)  ·  Takao Ohnuma, MD (1)  ·  Wells Messersmith, MD (1)

Results publications

PMID 22338014, PMID 23841031, PMID 24777753, PMID 26091808, PMID 26489442, PMID 26945010, PMID 27400247, PMID 29144985